Nautilus Posts First Revenue, Narrows Loss; Delays Broadscale Assay
NAUT has more than doubled off its 52-week low of $0.62.
Summary
Nautilus Biotechnology reported its first-ever revenue in Q2 2026, driven by a grant from the Michael J. Fox Foundation and initial service sales under its Iterative Mapping Early Access Program. The net loss narrowed to $14.47 million from a year ago, helped by a 7% decline in operating expenses to $15.94 million. However, the company indefinitely delayed its broadscale assay and pushed the Voyager platform launch to early 2027 pre-orders and mid-2027 shipments. This follows a July 27 8-K that first disclosed the revenue milestone and assay delay. The revenue milestone validates the platform's early commercial traction, but the assay delay raises questions about the timeline to full commercialization. With a strong cash position of $143.4 million as of Q1, the company has runway to execute on its revised roadmap. Tau and AKT1 consumable kits are expected in mid-2027, providing nearer-term product catalysts.
At the time of this announcement, NAUT was trading at $1.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $211M. The 52-week trading range was $0.62 to $4.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.